世界のユーイング肉腫治療市場2024-2028

◆英語タイトル:Global Ewing's Sarcoma Treatment Market 2024-2028

Technavioが発行した調査報告書(IRTNTR72933-23)◆商品コード:IRTNTR72933-23
◆発行会社(リサーチ会社):Technavio
◆発行日:2023年10月26日
◆ページ数:約120
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他地域
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

ユーイング肉腫治療の世界市場 2024-2028ユーイング肉腫治療市場は、2023-2028年に2億509万米ドルの成長が予測され、予測期間中のCAGRは6.26%で加速すると予測されます。当レポートでは、ユーイング肉腫治療市場について、市場規模や予測、動向、成長促進要因、課題などの全体的な分析に加え、約25のベンダーを網羅したベンダー分析も掲載しています。
当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。この市場を牽引しているのは、ユーイング肉腫に対する認知度の向上と資金提供、ユーイング肉腫治療に対する規制上の優遇措置、財政支援プログラムや償還制度などです。

Technavioのユーイング肉腫治療市場は以下のように区分されています。
エンドユーザー別
- 病院
- 専門クリニック
- その他

タイプ別
- 併用療法
- 単剤療法

地域別
- 北米
- 欧州
- アジア
- その他の地域(ROW)

本調査では、今後数年間のユーイング肉腫治療市場の成長を促進する主な理由の一つとして、再生療法の出現を挙げています。また、CRISPR-cas9技術の出現と強力な研究助成金は、市場の大きな需要につながるでしょう。

この調査レポートは、ユーイング肉腫治療市場を調査・分析した結果をまとめたものです。
- ユーイング肉腫治療市場規模
- ユーイング肉腫治療市場予測
- ユーイング肉腫治療市場産業分析

強固なベンダー分析は、クライアントが市場での地位を向上できるように設計されており、これに沿って、本レポートでは、Actiza Pharmaceutical Pvt. Ltd., Advantech Co. Ltd., Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol Myers Squibb Co., Cellectar Biosciences Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Fresenius Kabi AG, GlaxoSmithKline Plc, Gradalis Inc., Johnson and Johnson, LGM Pharma LLC, Merck and Co. Inc., Novartis AG, Ocean pharmaceutical, Pfizer Inc., PharmaMar SA, Salvavidas, and UPMC Hillman Cancer Center.などの企業情報が含まれています。また、ユーイング肉腫治療市場分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。当レポートでは、主要ベンダーの分析に加え、包括的な市場とベンダーの状況を掲載しています。
当出版社では、利益、価格、競争、プロモーションなどの主要パラメータの分析を通じて、複数の情報源からのデータを調査、統合、総括することにより、市場の詳細な姿を提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

1 エグゼクティブサマリー
2 市場状況
3 市場規模
4 過去の市場規模
5 ファイブフォース分析
6 ユーイング肉腫治療の世界市場:エンドユーザー別市場分析
7 ユーイング肉腫治療の世界市場:タイプ別市場分析
8 顧客状況
9 地域別状況
10 推進要因・課題・動向
11 企業状況
12 企業分析
13 付録

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Global Ewings sarcoma treatment market 2018 – 2022
o Exhibit 18: Historic Market Size – Data Table on global ewings sarcoma treatment market 2018 – 2022 ($ million)
o 4.2 End-user Segment Analysis 2018 – 2022
o Exhibit 19: Historic Market Size – End-user Segment 2018 – 2022 ($ million)
o 4.3 Type Segment Analysis 2018 – 2022
o Exhibit 20: Historic Market Size – Type Segment 2018 – 2022 ($ million)
o 4.4 Geography Segment Analysis 2018 – 2022
o Exhibit 21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
o 4.5 Country Segment Analysis 2018 – 2022
o Exhibit 22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2023 and 2028
• 6 Market Segmentation by End-user
o 6.1 Market segments
o Exhibit 30: Chart on End-user – Market share 2023-2028 (%)
o Exhibit 31: Data Table on End-user – Market share 2023-2028 (%)
o 6.2 Comparison by End-user
o Exhibit 32: Chart on Comparison by End-user
o Exhibit 33: Data Table on Comparison by End-user
o 6.3 Hospitals – Market size and forecast 2023-2028
o Exhibit 34: Chart on Hospitals – Market size and forecast 2023-2028 ($ million)
o Exhibit 35: Data Table on Hospitals – Market size and forecast 2023-2028 ($ million)
o Exhibit 36: Chart on Hospitals – Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Hospitals – Year-over-year growth 2023-2028 (%)
o 6.4 Specialty clinics – Market size and forecast 2023-2028
o Exhibit 38: Chart on Specialty clinics – Market size and forecast 2023-2028 ($ million)
o Exhibit 39: Data Table on Specialty clinics – Market size and forecast 2023-2028 ($ million)
o Exhibit 40: Chart on Specialty clinics – Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Specialty clinics – Year-over-year growth 2023-2028 (%)
o 6.5 Others – Market size and forecast 2023-2028
o Exhibit 42: Chart on Others – Market size and forecast 2023-2028 ($ million)
o Exhibit 43: Data Table on Others – Market size and forecast 2023-2028 ($ million)
o Exhibit 44: Chart on Others – Year-over-year growth 2023-2028 (%)
o Exhibit 45: Data Table on Others – Year-over-year growth 2023-2028 (%)
o 6.6 Market opportunity by End-user
o Exhibit 46: Market opportunity by End-user ($ million)
o Exhibit 47: Data Table on Market opportunity by End-user ($ million)
• 7 Market Segmentation by Type
o 7.1 Market segments
o Exhibit 48: Chart on Type – Market share 2023-2028 (%)
o Exhibit 49: Data Table on Type – Market share 2023-2028 (%)
o 7.2 Comparison by Type
o Exhibit 50: Chart on Comparison by Type
o Exhibit 51: Data Table on Comparison by Type
o 7.3 Combination therapy – Market size and forecast 2023-2028
o Exhibit 52: Chart on Combination therapy – Market size and forecast 2023-2028 ($ million)
o Exhibit 53: Data Table on Combination therapy – Market size and forecast 2023-2028 ($ million)
o Exhibit 54: Chart on Combination therapy – Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Combination therapy – Year-over-year growth 2023-2028 (%)
o 7.4 Monotherapy – Market size and forecast 2023-2028
o Exhibit 56: Chart on Monotherapy – Market size and forecast 2023-2028 ($ million)
o Exhibit 57: Data Table on Monotherapy – Market size and forecast 2023-2028 ($ million)
o Exhibit 58: Chart on Monotherapy – Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Monotherapy – Year-over-year growth 2023-2028 (%)
o 7.5 Market opportunity by Type
o Exhibit 60: Market opportunity by Type ($ million)
o Exhibit 61: Data Table on Market opportunity by Type ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share by geography 2023-2028 (%)
o Exhibit 64: Data Table on Market share by geography 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2023-2028
o Exhibit 67: Chart on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 68: Data Table on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 69: Chart on North America – Year-over-year growth 2023-2028 (%)
o Exhibit 70: Data Table on North America – Year-over-year growth 2023-2028 (%)
o 9.4 Europe – Market size and forecast 2023-2028
o Exhibit 71: Chart on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 72: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 73: Chart on Europe – Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on Europe – Year-over-year growth 2023-2028 (%)
o 9.5 Asia – Market size and forecast 2023-2028
o Exhibit 75: Chart on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 76: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 77: Chart on Asia – Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Asia – Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2023-2028
o Exhibit 79: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 80: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 81: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o 9.7 US – Market size and forecast 2023-2028
o Exhibit 83: Chart on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 84: Data Table on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 85: Chart on US – Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on US – Year-over-year growth 2023-2028 (%)
o 9.8 Canada – Market size and forecast 2023-2028
o Exhibit 87: Chart on Canada – Market size and forecast 2023-2028 ($ million)
o Exhibit 88: Data Table on Canada – Market size and forecast 2023-2028 ($ million)
o Exhibit 89: Chart on Canada – Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on Canada – Year-over-year growth 2023-2028 (%)
o 9.9 UK – Market size and forecast 2023-2028
o Exhibit 91: Chart on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 92: Data Table on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 93: Chart on UK – Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on UK – Year-over-year growth 2023-2028 (%)
o 9.10 Germany – Market size and forecast 2023-2028
o Exhibit 95: Chart on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 96: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 97: Chart on Germany – Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on Germany – Year-over-year growth 2023-2028 (%)
o 9.11 Japan – Market size and forecast 2023-2028
o Exhibit 99: Chart on Japan – Market size and forecast 2023-2028 ($ million)
o Exhibit 100: Data Table on Japan – Market size and forecast 2023-2028 ($ million)
o Exhibit 101: Chart on Japan – Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on Japan – Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity by geography
o Exhibit 103: Market opportunity by geography ($ million)
o Exhibit 104: Data Tables on Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 Advantech Co. Ltd.
o Exhibit 111: Advantech Co. Ltd. – Overview
o Exhibit 112: Advantech Co. Ltd. – Business segments
o Exhibit 113: Advantech Co. Ltd. – Key offerings
o Exhibit 114: Advantech Co. Ltd. – Segment focus
o 12.4 Amneal Pharmaceuticals Inc.
o Exhibit 115: Amneal Pharmaceuticals Inc. – Overview
o Exhibit 116: Amneal Pharmaceuticals Inc. – Business segments
o Exhibit 117: Amneal Pharmaceuticals Inc. – Key news
o Exhibit 118: Amneal Pharmaceuticals Inc. – Key offerings
o Exhibit 119: Amneal Pharmaceuticals Inc. – Segment focus
o 12.5 Baxter International Inc.
o Exhibit 120: Baxter International Inc. – Overview
o Exhibit 121: Baxter International Inc. – Business segments
o Exhibit 122: Baxter International Inc. – Key news
o Exhibit 123: Baxter International Inc. – Key offerings
o Exhibit 124: Baxter International Inc. – Segment focus
o 12.6 Bristol Myers Squibb Co.
o Exhibit 125: Bristol Myers Squibb Co. – Overview
o Exhibit 126: Bristol Myers Squibb Co. – Product / Service
o Exhibit 127: Bristol Myers Squibb Co. – Key news
o Exhibit 128: Bristol Myers Squibb Co. – Key offerings
o 12.7 Cellectar Biosciences Inc.
o Exhibit 129: Cellectar Biosciences Inc. – Overview
o Exhibit 130: Cellectar Biosciences Inc. – Product / Service
o Exhibit 131: Cellectar Biosciences Inc. – Key offerings
o 12.8 Daiichi Sankyo Co. Ltd.
o Exhibit 132: Daiichi Sankyo Co. Ltd. – Overview
o Exhibit 133: Daiichi Sankyo Co. Ltd. – Product / Service
o Exhibit 134: Daiichi Sankyo Co. Ltd. – Key news
o Exhibit 135: Daiichi Sankyo Co. Ltd. – Key offerings
o 12.9 Eli Lilly and Co.
o Exhibit 136: Eli Lilly and Co. – Overview
o Exhibit 137: Eli Lilly and Co. – Product / Service
o Exhibit 138: Eli Lilly and Co. – Key news
o Exhibit 139: Eli Lilly and Co. – Key offerings
o 12.10 Fresenius Kabi AG
o Exhibit 140: Fresenius Kabi AG – Overview
o Exhibit 141: Fresenius Kabi AG – Business segments
o Exhibit 142: Fresenius Kabi AG – Key news
o Exhibit 143: Fresenius Kabi AG – Key offerings
o Exhibit 144: Fresenius Kabi AG – Segment focus
o 12.11 GlaxoSmithKline Plc
o Exhibit 145: GlaxoSmithKline Plc – Overview
o Exhibit 146: GlaxoSmithKline Plc – Business segments
o Exhibit 147: GlaxoSmithKline Plc – Key news
o Exhibit 148: GlaxoSmithKline Plc – Key offerings
o Exhibit 149: GlaxoSmithKline Plc – Segment focus
o 12.12 Gradalis Inc.
o Exhibit 150: Gradalis Inc. – Overview
o Exhibit 151: Gradalis Inc. – Product / Service
o Exhibit 152: Gradalis Inc. – Key offerings
o 12.13 Johnson and Johnson
o Exhibit 153: Johnson and Johnson – Overview
o Exhibit 154: Johnson and Johnson – Business segments
o Exhibit 155: Johnson and Johnson – Key news
o Exhibit 156: Johnson and Johnson – Key offerings
o Exhibit 157: Johnson and Johnson – Segment focus
o 12.14 Novartis AG
o Exhibit 158: Novartis AG – Overview
o Exhibit 159: Novartis AG – Business segments
o Exhibit 160: Novartis AG – Key offerings
o Exhibit 161: Novartis AG – Segment focus
o 12.15 Ocean pharmaceutical
o Exhibit 162: Ocean pharmaceutical – Overview
o Exhibit 163: Ocean pharmaceutical – Product / Service
o Exhibit 164: Ocean pharmaceutical – Key offerings
o 12.16 Pfizer Inc.
o Exhibit 165: Pfizer Inc. – Overview
o Exhibit 166: Pfizer Inc. – Product / Service
o Exhibit 167: Pfizer Inc. – Key news
o Exhibit 168: Pfizer Inc. – Key offerings
o 12.17 PharmaMar SA
o Exhibit 169: PharmaMar SA – Overview
o Exhibit 170: PharmaMar SA – Business segments
o Exhibit 171: PharmaMar SA – Key offerings
o Exhibit 172: PharmaMar SA – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 173: Inclusions checklist
o Exhibit 174: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 175: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 176: Research methodology
o Exhibit 177: Validation techniques employed for market sizing
o Exhibit 178: Information sources
o 13.5 List of abbreviations
o Exhibit 179: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by End-user
Exhibits6: Executive Summary – Chart on Market Segmentation by Type
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size – Data Table on global ewings sarcoma treatment market 2018 – 2022 ($ million)
Exhibits19: Historic Market Size – End-user Segment 2018 – 2022 ($ million)
Exhibits20: Historic Market Size – Type Segment 2018 – 2022 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
Exhibits22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
Exhibits23: Five forces analysis – Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants – Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes – Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry – Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition – Five forces 2023 and 2028
Exhibits30: Chart on End-user – Market share 2023-2028 (%)
Exhibits31: Data Table on End-user – Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by End-user
Exhibits33: Data Table on Comparison by End-user
Exhibits34: Chart on Hospitals – Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Hospitals – Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Hospitals – Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Hospitals – Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Specialty clinics – Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on Specialty clinics – Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on Specialty clinics – Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Specialty clinics – Year-over-year growth 2023-2028 (%)
Exhibits42: Chart on Others – Market size and forecast 2023-2028 ($ million)
Exhibits43: Data Table on Others – Market size and forecast 2023-2028 ($ million)
Exhibits44: Chart on Others – Year-over-year growth 2023-2028 (%)
Exhibits45: Data Table on Others – Year-over-year growth 2023-2028 (%)
Exhibits46: Market opportunity by End-user ($ million)
Exhibits47: Data Table on Market opportunity by End-user ($ million)
Exhibits48: Chart on Type – Market share 2023-2028 (%)
Exhibits49: Data Table on Type – Market share 2023-2028 (%)
Exhibits50: Chart on Comparison by Type
Exhibits51: Data Table on Comparison by Type
Exhibits52: Chart on Combination therapy – Market size and forecast 2023-2028 ($ million)
Exhibits53: Data Table on Combination therapy – Market size and forecast 2023-2028 ($ million)
Exhibits54: Chart on Combination therapy – Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Combination therapy – Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Monotherapy – Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Monotherapy – Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Monotherapy – Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Monotherapy – Year-over-year growth 2023-2028 (%)
Exhibits60: Market opportunity by Type ($ million)
Exhibits61: Data Table on Market opportunity by Type ($ million)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share by geography 2023-2028 (%)
Exhibits64: Data Table on Market share by geography 2023-2028 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America – Market size and forecast 2023-2028 ($ million)
Exhibits68: Data Table on North America – Market size and forecast 2023-2028 ($ million)
Exhibits69: Chart on North America – Year-over-year growth 2023-2028 (%)
Exhibits70: Data Table on North America – Year-over-year growth 2023-2028 (%)
Exhibits71: Chart on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits72: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits73: Chart on Europe – Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on Europe – Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on Asia – Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Asia – Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on US – Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on US – Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on US – Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on US – Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on Canada – Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on Canada – Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on Canada – Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on Canada – Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on UK – Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on UK – Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on UK – Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on UK – Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on Germany – Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on Germany – Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on Japan – Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on Japan – Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on Japan – Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on Japan – Year-over-year growth 2023-2028 (%)
Exhibits103: Market opportunity by geography ($ million)
Exhibits104: Data Tables on Market opportunity by geography ($ million)
Exhibits105: Impact of drivers and challenges in 2023 and 2028
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: Advantech Co. Ltd. – Overview
Exhibits112: Advantech Co. Ltd. – Business segments
Exhibits113: Advantech Co. Ltd. – Key offerings
Exhibits114: Advantech Co. Ltd. – Segment focus
Exhibits115: Amneal Pharmaceuticals Inc. – Overview
Exhibits116: Amneal Pharmaceuticals Inc. – Business segments
Exhibits117: Amneal Pharmaceuticals Inc. – Key news
Exhibits118: Amneal Pharmaceuticals Inc. – Key offerings
Exhibits119: Amneal Pharmaceuticals Inc. – Segment focus
Exhibits120: Baxter International Inc. – Overview
Exhibits121: Baxter International Inc. – Business segments
Exhibits122: Baxter International Inc. – Key news
Exhibits123: Baxter International Inc. – Key offerings
Exhibits124: Baxter International Inc. – Segment focus
Exhibits125: Bristol Myers Squibb Co. – Overview
Exhibits126: Bristol Myers Squibb Co. – Product / Service
Exhibits127: Bristol Myers Squibb Co. – Key news
Exhibits128: Bristol Myers Squibb Co. – Key offerings
Exhibits129: Cellectar Biosciences Inc. – Overview
Exhibits130: Cellectar Biosciences Inc. – Product / Service
Exhibits131: Cellectar Biosciences Inc. – Key offerings
Exhibits132: Daiichi Sankyo Co. Ltd. – Overview
Exhibits133: Daiichi Sankyo Co. Ltd. – Product / Service
Exhibits134: Daiichi Sankyo Co. Ltd. – Key news
Exhibits135: Daiichi Sankyo Co. Ltd. – Key offerings
Exhibits136: Eli Lilly and Co. – Overview
Exhibits137: Eli Lilly and Co. – Product / Service
Exhibits138: Eli Lilly and Co. – Key news
Exhibits139: Eli Lilly and Co. – Key offerings
Exhibits140: Fresenius Kabi AG – Overview
Exhibits141: Fresenius Kabi AG – Business segments
Exhibits142: Fresenius Kabi AG – Key news
Exhibits143: Fresenius Kabi AG – Key offerings
Exhibits144: Fresenius Kabi AG – Segment focus
Exhibits145: GlaxoSmithKline Plc – Overview
Exhibits146: GlaxoSmithKline Plc – Business segments
Exhibits147: GlaxoSmithKline Plc – Key news
Exhibits148: GlaxoSmithKline Plc – Key offerings
Exhibits149: GlaxoSmithKline Plc – Segment focus
Exhibits150: Gradalis Inc. – Overview
Exhibits151: Gradalis Inc. – Product / Service
Exhibits152: Gradalis Inc. – Key offerings
Exhibits153: Johnson and Johnson – Overview
Exhibits154: Johnson and Johnson – Business segments
Exhibits155: Johnson and Johnson – Key news
Exhibits156: Johnson and Johnson – Key offerings
Exhibits157: Johnson and Johnson – Segment focus
Exhibits158: Novartis AG – Overview
Exhibits159: Novartis AG – Business segments
Exhibits160: Novartis AG – Key offerings
Exhibits161: Novartis AG – Segment focus
Exhibits162: Ocean pharmaceutical – Overview
Exhibits163: Ocean pharmaceutical – Product / Service
Exhibits164: Ocean pharmaceutical – Key offerings
Exhibits165: Pfizer Inc. – Overview
Exhibits166: Pfizer Inc. – Product / Service
Exhibits167: Pfizer Inc. – Key news
Exhibits168: Pfizer Inc. – Key offerings
Exhibits169: PharmaMar SA – Overview
Exhibits170: PharmaMar SA – Business segments
Exhibits171: PharmaMar SA – Key offerings
Exhibits172: PharmaMar SA – Segment focus
Exhibits173: Inclusions checklist
Exhibits174: Exclusions checklist
Exhibits175: Currency conversion rates for US$
Exhibits176: Research methodology
Exhibits177: Validation techniques employed for market sizing
Exhibits178: Information sources
Exhibits179: List of abbreviations



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のユーイング肉腫治療市場2024-2028(Global Ewing's Sarcoma Treatment Market 2024-2028)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆